JMIR Publications

ABSTRACT

Background:

Clinical trial management is a complex, multi-stakeholder process fraught with inefficiencies that delay drug development and inflate costs. Multi-agent reinforcement learning (MARL) offers a promising paradigm for coordinating diverse operational tasks, but its application in the highly regulated and safety-critical domain of clinical trials remains underexplored.

Objective:

This paper introduces MEDRAIL, a novel MARL architecture specifically designed to address the unique challenges of clinical trial management. We describe its core components, coordination mechanisms, and integration with formal verification methods to ensure safety and regulatory compliance. We present results from a simulation study designed to evaluate the potential impact of such an architecture.

Methods:

The MEDRAIL architecture comprises specialized AI agents for key trial functions. These agents are designed to learn and adapt their strategies through a hierarchical MARL framework integrated with Linear Temporal Logic-based formal verification to provide safety guarantees. To evaluate the potential of this proposed architecture, we conducted a comparative Monte Carlo simulation study (N=1000 runs). This study compared a model of the MEDRAIL system's expected performance against a traditional management baseline. The distinct capabilities of the MEDRAIL system (e.g., enhanced monitoring) were modeled using pre-defined performance parameters based on the projected capabilities of the final AI system.

Results:

The simulation results suggest that a MEDRAIL system has the potential to deliver significant improvements across key performance indicators. The MEDRAIL model achieved a 93.7% detection rate for serious adverse events (SAEs) and a 92.9% detection rate for protocol deviations, representing a 35.2% and 33.4% improvement over the baseline model, respectively. This enhanced monitoring capability contributed to a projected 69.9% reduction in overall risk-adjusted trial costs. Operationally, the MEDRAIL model also reduced timeline risk by accelerating patient enrollment by 8.6%.

Conclusions:

The proposed MEDRAIL MARL architecture represents a promising new approach for AI in clinical trial management. By enabling adaptive coordination and ensuring safety through formal methods, it has the potential to streamline trial processes, enhance patient safety and data integrity, and dramatically reduce the financial risk associated with clinical research. Our simulation study validates the potential of this approach. Future work will focus on the full implementation and validation of the autonomous learning agents and subsequent real-world deployment.